©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Promotion of Fibroblast Adhesion by Triple-helical Peptide Models of Type I Collagen-derived Sequences (*)

(Received for publication, January 26, 1996)

Beate Grab (1) (3)(§) Andrew J. Miles (1) (3) Leo T. Furcht (1) (3)(¶) Gregg B. Fields (1) (3) (2)(**)

From the  (1)Departments of Laboratory Medicine and Pathology, (2)Biochemistry, and (3)The Biomedical Engineering Center, University of Minnesota, Minneapolis, Minnesota 55455

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The dissection of the activities mediated by type I collagen requires an approach by which the influence of triple-helical conformation can be evaluated. The alpha(1)beta(1) and alpha(2)beta(1) integrin binding sites within type I collagen are dependent upon triple-helical conformation and contained within residues 124-822 from alpha1(I). Seven alpha1(I)-derived triple-helical peptides (THPs) were synthesized based on charge clustering (alpha1(I)256-270, alpha1(I)385-396, alpha1(I)406-417, alpha1(I)415-423, alpha1(I)448-456, alpha1(I)496-507, and alpha1(I)526-537). Three additional THPs were synthesized (alpha1(I)85-96, alpha1(I)433-441, and alpha1(I)772-786) based on previously described or proposed activities (Kleinman, H. K., McGoodwin, E. B., Martin, G. R., Klebe, R. J., Fietzek, P. P., and Wooley, D. E.(1978) J. Biol. Chem. 253, 5642-5646; Staatz, W. D., Fok, K. F., Zutter, M. M., Adams, S. P., Rodriguez, B. A., and Santoro, S. A.(1991) J. Biol. Chem. 266, 7363-7367; San Antonio, J. D., Lander, A. D., Karnovsky, M. J., and Slayter, H. S.(1994) J. Cell Biol. 125, 1179-1188). Of the ten THPs, alpha1(I)772-786 THP had the greatest activity, with half-maximal normal dermal fibroblast adhesion occurring at a peptide concentration of 1.6 µM. Triple-helicity was essential for activity of this sequence, as the non-triple-helical peptide analog (alpha1(I)772-786 SSP) exhibited considerably lower levels of cell adhesion promotion even at peptide concentrations as high as 100 µM. Within the sequence itself, residues 784-786 (Gly-Leu-Hyp) were important for cellular recognition, as the alpha1(I)772-783 THP had greatly reduced cell adhesion activity compared with alpha1(I)772-786 THP. Preliminary studies indicate that the beta(1) integrin subunit mediates fibroblast adhesion to alpha1(I)772-786 THP. The identification of fibroblast integrin binding sites within type I collagen may have important implications for understanding collagen metabolism.


INTRODUCTION

Collagens are important structural components of the extracellular matrix (ECM). (^1)They are distinguished by their triple-helical conformation composed of three chains with a repeating Gly-X-Y sequence motif. In addition to providing the structure of connective tissue, collagens can mediate intracellular communication. Cell-collagen interactions play a role in a number of processes including cell migration(1, 2) , collagen catabolism(3, 4) , and the aggregation of platelets(5, 6, 7, 8, 9, 10, 11, 12, 13) . One approach for developing novel therapies for diseases linked to ECM interactions, such as tumor cell metastasis, atherosclerosis, inflammation, and thrombosis, or to better understand normal processes such as wound healing, is to identify cellular recognition sites within collagen molecules and dissect the structure-activity relationship for receptor-ligand binding(14) .

Type I collagen, the most abundant protein in higher vertebrates, is composed of two identical alpha1 chains and an alpha2 chain. Cyanogen bromide (CB) fragments of the alpha1 chain have been used to locate integrin-mediated cell binding sites within type I collagen. The alpha1(I)CB3 fragment (residues 403-551) and the alpha1(I)CB8 fragment (residues 124-402) contain binding sites for alpha(1)beta(1) integrin(2, 15) . alpha1(I)CB3 also contains a binding site for the hepatocyte alpha(2)beta(1) integrin(15) , while alpha1(I)CB3, alpha1(I)CB7 (residues 552-822), and alpha1(I)CB8 contain binding sites for the platelet alpha(2)beta(1) integrin(12, 13, 16) .

Several distinct sequences derived from type I collagen CB fragments have been identified as cell adhesion sites. The adhesion of Chinese hamster ovary cells to type I collagen is inhibited by the 757-791 sequence located within the alpha1(I)CB7 fragment(17) . A peptide incorporating residues alpha1(I)769-783 supports human fibroblast adhesion and migration and inhibits human fibroblast and human T-lymphocyte attachment to type I collagen(18, 19) . By using short synthetic peptides, an alpha(2)beta(1) integrin binding site could be identified containing the minimal sequence Asp-Gly-Glu-Ala(20) . This sequence corresponded to residues 435-438 within the alpha1(I)CB3 fragment. The alpha1(I)434-438 peptide inhibits adhesion of platelets and breast carcinoma cells to type I collagen in a concentration-dependent manner (20) and, not surprisingly, was not effective at inhibiting alpha(2)beta(1)-mediated chondrosarcoma cell adhesion to type II collagen(21) .

There may be two types of active sequences within type I collagen. The activity of some sequences may require triple-helicity, while others might be nonfunctional when contained in native, triple-helical conformation but revealed in the denatured state(33) . Only single-stranded peptides (SSPs) have been utilized in prior studies on the cellular activities of type I collagen sequences. However, the triple-helical conformation of collagen has been shown to be important (if not crucial) for influencing cell adhesion(2, 7, 13, 15, 22, 23, 24, 25) , cell spreading(26) , cell migration(1) , matrix metalloproteinase (MMP) binding(27) , and human platelet adhesion and aggregation(13, 28, 29) . Conversely, cell adhesion to denatured, but not native, collagen can be inhibited by linear peptides containing Arg-Gly-Asp sequences(15, 30, 31, 32, 33) . Denatured collagen Arg-Gly-Asp sites are bound by the alpha(5)beta(1)(15) or alpha(v)beta(3) integrin(30) . To fully understand the role of collagen in ECM remodeling requires delineation of native collagen active sites from denatured collagen sites.

In the present study, we have examined potential cellular recognition sites within type I collagen and studied the significance of triple-helical conformation. Sequences were derived from alpha1(I)CB fragments that possess integrin binding sites. To utilize relatively short sequences (leq15 residues) and yet ensure triple-helical conformation under biological assay conditions, we applied a methodology developed specifically for the assembly of collagen-model, triple-helical peptides (THPs)(34, 35) . A total of 11 THPs have been synthesized. Cellular recognition was studied by assaying normal human dermal fibroblast adhesion to these THPs. The influence of triple-helicity was examined by comparing the activity of a SSP and THP containing the same collagen-derived sequence. The potential involvement of integrins in mediating cell adhesion to a specific THP was evaluated by screening monoclonal antibodies (mAbs) against integrin subunits as inhibitors of cell adhesion assays.


EXPERIMENTAL PROCEDURES

Materials

All standard peptide synthesis chemicals and solvents were analytical reagent grade or better and purchased from Applied Biosystems, Inc. (Foster City, CA) or Fisher Scientific (Pittsburgh, PA). Fmoc-Gly-Sasrin resin (substitution level = 0.7 or 0.65 mmol/g) and Fmoc-Gly-Pro-Hyp were purchased from Bachem Biosciences Inc. (Philadelphia, PA). Fmoc-DMPAMP resin (substitution level = 0.46 mmol/g) was from Novabiochem (La Jolla, CA) and Fmoc-Met, Fmoc-Hyp(tBu), and Fmoc-Ahx from Advanced ChemTech (Louisville, KY). All other Fmoc-amino acid derivatives were from Novabiochem or Perseptive Biosystems (Framingham, MA). All amino acids are of L-configuration. HOBt was purchased from Novabiochem, HBTU from Richelieu Biotechnologies (St. Hyacinthe, Quebec), DIEA from Fisher Scientific, and DBU and DIPCDI from Aldrich. The synthesis and characterization of a generic THP containing 8 repeats of Gly-Pro-Hyp (designated GPP*) has been described previously (34) . Monoclonal antibody (mAb) P5D2 was prepared against the beta(1) integrin subunit using methods described previously (36) . A mAb prepared against the alpha(1) integrin subunit (5E8D9) was obtained from Upstate Biotechnology (Lake Placid, NY). mAbs prepared against the integrin subunits alpha(2) (P1E6), alpha(3) (P1B5), and alpha(5) (P1D6) were purchased from Chemicon International (Temecula, CA). The anti-alpha(3) mAb was obtained as ascites fluid (2.5 mg of IgG/ml of ascites), while the anti-alpha(2) mAb was obtained as both ascites fluid (2.5 mg of IgG/ml of ascites) and purified IgG; all other mAbs were purified IgGs. Purified normal mouse IgG was purchased from Organon Teknika Corp. (Durham, NC).

Preparation of (N-Tris(Fmoc-Ahx)-Lys-Lys)-Tyr(tBu)-Gly-Sasrin Resin

0.97 g of Fmoc-Tyr(tBu) (2.1 mmol), 1.96 g of Fmoc-Lys(Dde) (2.1 mmol), and 1.96 g of Fmoc-Lys(Dde) (2.1 mmol) were sequentially coupled to 1.0 g of Fmoc-Gly-Sasrin resin (substitution level = 0.7 mmol) in a shaker. Fmoc-protected amino acids were preactivated with 0.32 g of HOBt (2.1 mmol) and 0.33 ml of DIPCDI (2.1 mmol) in 15 ml of DMF at room temperature for 15 min. The preactivated amino acid solution was then added together with 0.30 ml of DIEA (2.1 mmol) to the resin, and coupling proceeded for 1 h at room temperature. Fmoc removal was by two treatments with 20 ml of piperidine-DMF (1:4) for 3 and 10 min. After coupling of the second Fmoc-Lys(Dde) and following Fmoc removal, cleavage of Dde protecting groups was achieved with 15 ml of hydrazine-DMF (1:49) for 2 h. 2.23 g of Fmoc-Ahx (6.3 mmol) was then coupled for 45 min to the free N- and N-amino groups after preactivation with 0.97 g of HOBt (6.3 mmol) and 0.99 ml of DIPCDI (6.3 mmol) and following addition of 0.89 ml of DIEA (6.3 mmol). The peptide-resin was washed three times with DMF. After each coupling and deprotection step, the completion of the reaction was examined by the ninhydrin test (37) .

Alternatively, the branched peptide-resin was synthesized by using HBTU/HOBt as coupling reagents. 1.95 mmol of the above-mentioned Fmoc-amino acids were coupled to 1 g of Fmoc-Gly-Sasrin resin (substitution level = 0.65 mmol/g) with 0.26 g of HOBt (1.95 mmol), 0.67 g of HBTU (1.76 mmol), and 0.63 ml of DIEA (3.71 mmol) in DMF without preactivation. The coupling was complete within 1 to 2 h. Fmoc and Dde removal were as described above. 2.07 g of Fmoc-Ahx (5.85 mmol) was coupled for 2 h to the liberated N- and N-amino groups by using 0.82 g of HOBt (6 mmol), 2.00 g of HBTU (5.3 mmol), and 1.90 ml of DIEA (11.05 mmol).

After assembly, branched peptide-resins were washed several times with DMF followed by dichloromethane. A small quantity of the branched peptides was deprotected and cleaved with water-TFA (1:19) for 1 h. After precipitation and washing twice in methyl t-butyl ether, the branched peptides were lyophilized to a colorless powder. The branched peptides were analyzed by either ESMS or FABMS, giving an (M + H) = 834.4 Da by ESMS and (M + H) = 834.6 Da by FABMS (theoretical (M + H) = 834.6 Da).

Triple-helical Peptide Synthesis and Purification

Incorporation of individual amino acids onto the branched peptide resin was performed initially by Fmoc solid-phase methodology on a Gilson AMS 422 Automated Multiple Peptide Synthesizer. The cycles for the Gilson AMS 422 were modified from those described previously (38) by using double couplings with 6-fold excess of Fmoc-amino acids. Addition of the 6 final repeats of Gly-Pro-Hyp was done manually in a shaker vessel. The couplings of the tripeptides to 0.11 g of peptide-resin (substitution = 0.26 mmol/g) were performed with 57 mg of Fmoc-Gly-Pro-Hyp (0.112 mmol), 17 mg of HOBt (0.112 mmol), 32 mg of HBTU (0.1 mmol), and 30 µl of DIEA (0.212 mmol) in DMF for 2-3 h. Deprotection of the Fmoc-peptide-resin was performed with DBU-piperidine-DMF (1:1:48) for 30 min, and the resin was subsequently washed three times with DMF.

The large-scale synthesis of peptide alpha1(I)772-786 THP was on an Applied Biosystems 431A Peptide Synthesizer. Peptide assembly, including final stepwise incorporation of individual Fmoc-Gly, Fmoc-Pro, and Fmoc-Hyp(tBu) residues, was performed by Fmoc solid-phase methodology as described (34) with several modifications. Coupling utilized 0.45 M HBTU, 0.50 M HOBt, and 0.95 M DIEA in DMF for 1 h, while Fmoc removal was achieved with 0.1 M HOBt in piperidine-1-methyl-2-pyrrolidinone (1:4) for 24 min and 6 min. The following cleavage procedure was applied for the large-scale synthesis of alpha1(I)772-786 THP and was modified for other THPs according to their side-chain protection(39) . 203 mg of the peptide-resin was Fmoc-deprotected with DBU-piperidine-DMF (1:1:48). Side-chain deprotection and cleavage was by treatment with water/thioanisole/TFA (1:1:18). The crude alpha1(I)772-786 THP was precipitated with methyl t-butyl ether, lyophilized, and 70 mg (from a total of 100 mg) was dissolved in 2.0 ml of water.

Preparative RP-HPLC purification was performed on a Rainin AutoPrep System with a Vydac 218TP152022 C(18) column (15-20 µm particle size, 300 Å pore size, 250 times 22 mm) at a flow rate of 5.0 ml/min. The elution gradient was 0-100% B in 100 min where A was 0.1% TFA in water and B was 0.1% TFA in acetonitrile. Detection was at 229 nm. A second purification was performed on the same system with a semipreparative Vydac 219TP510 diphenyl column (5 µm particle size, 300 Å pore size, 250 times 10 mm) at a flow rate of 2 ml/min. The elution gradient was 0-70% B in 70 min with the described eluents. The purification of alpha1(I)772-786 THP was described recently(40) ; yield was 18.1 mg (15.2% of theoretical).

Single-stranded Peptide Synthesis

A peptide representing the alpha1(I)772-786 sequence of type I collagen was synthesized on Fmoc-DMPAMP resin (substitution level = 0.46 mmol/g) using Fmoc methodology on an Applied Biosystems 431A Peptide Synthesizer(41, 42) . Following synthesis, the peptide-resin was cleaved with ethanedithiol/thioanisole/phenol/water/TFA (2.5:5:5:5:82.5) (39) and purified by RP-HPLC(42) . Analysis by FABMS gave (M + H) = 1420.4 Da (theoretical (M + H) = 1420.6 Da).

Peptide Analysis

Analytical RP-HPLC was performed on a Hewlett-Packard 1090 Liquid Chromatograph equipped with a Vydac 219TP54 diphenyl column (5 µm particle size, 300 Å pore size, 250 times 4.6 mm). The flow rate was 1.0 ml/min. Eluants were 0.1% TFA in water (A) and 0.1% TFA in acetonitrile (B). The elution gradient was 0-50% B in 50 min with a flow of 1 ml/min. Detection was at 229 nm.

Edman degradation sequence analysis was performed on an Applied Biosystems 477A Protein Sequencer/120A Analyzer as described(42, 43) for ``embedded'' (noncovalent) sequencing. FAB mass spectra were obtained on a VG 7070-HF mass spectrometer and ES mass spectra on a Sciex API III double quadrupole mass spectrometer. Laser desorption mass spectrometry was performed on the Kratos Kompact MALDI matrix-assisted laser desorption time-of-flight mass spectrometer. Circular dichroism (CD) spectroscopy was performed on a Jasco 710 spectropolarimeter using a 0.01-cm cell. Thermal transition curves were obtained by recording the molar ellipticity ([]) in the range of 10-80 °C at = 225 nm.

Cell Adhesion Assays

Adhesion assays were as described previously (44) with some alterations. Normal human dermal fibroblasts (NHDF) (Clonetics, San Diego, CA) were cultured on fibroblast growth medium from the same company. Cell attachment assays were performed in 96-well polystyrene Immulon 1 microtiter plates (Dynatech Laboratories Inc., Chantilly, VA). Peptides were dissolved in PBS and absorbed onto wells overnight at 37 °C in a humidified incubator with 5% (v/v) CO(2). Cells were labeled overnight with 200 µCi/ml S (DuPont NEN). Nonspecific binding sites were blocked with 2 mg/ml bovine serum albumin (Pentax, Miles Laboratories, Naperville, IL) in PBS for 2 h at 37 °C. NHDF cells were detached with trypsin/EDTA solution and, after release of the cells, the flask was rinsed quickly with HEPES-buffered saline solution and trypsin neutralizing solution (all from Clonetics). The cells were resuspended to 5 times 10^4/ml in fibroblast growth medium. Aliquots of 75 µl of the cell suspension were added to the plate wells and allowed to adhere for 30 min at 37 °C. For adhesion assays, wells were washed 3 times with 2 mg/ml bovine serum albumin in Ca/Mg PBS. 150 µl of Microscint-40 (Packard Instrument Co.) were added and the plates were read on a Beckman LS 6500 scintillation counter (Beckman Instruments). Adhesion percentages were based on total counts of radioactivity added to each well.

Inhibition of NHDFs was monitored in the presence of soluble synthetic peptides or mAbs generated against the alpha(1), alpha(2), alpha(3), alpha(5), and beta(1) integrin subunits to determine the cell surface receptor recognizing the alpha1(I)772-786 THP. Competition of cell adhesion was performed on surfaces coated with 5 µg/ml type I collagen (half-maximal cell adhesion) or with 10 µM alpha1(I)772-786 THP using methods described previously(44, 45) . Cells were preincubated for 20 or 30 min at 37 °C with various concentrations of potential inhibitory peptides or antibodies. The cells were then, in the continued presence of the potential inhibitor, added to the wells and allowed to adhere for 30 min at 37 °C. The cells remained viable in the inhibitory peptide-cell solution based upon exclusion of trypan blue dye.


RESULTS

Synthesis and Cellular Activities of Crude Triple-helical Type I Collagen Model Peptides

Four criteria were used for the identification of potential active sequences from collagen alpha1(I). First, sequences would be from CB fragments that contained integrin binding sites (alpha1(I)CB3, alpha1(I)CB7, and alpha1(I)CB8)). Second, sequences containing charge clusters were considered, as several active sequences from type IV collagen have a clustering of charged residues (35, 44, 46, 47, 48) . Third, sequences described previously to have binding activities, such as alpha1(I)85-96(49) , alpha1(I)433-441(20) , and alpha1(I)769-783 (17) were utilized. Fourth, sequences were 9-15 residues in length, as prior studies on type IV collagen had shown this length to be sufficient to establish cellular activities(35, 44) . For initial screening purposes, 10 sequences from the alpha1(I) chain (50, 51, 52, 53) were examined (Table 1). THPs containing these sequences were assembled using a methodology for the solid-phase synthesis of branched triple-helical peptides(34, 35) . Three nascent peptide chains were carboxyl-terminally linked through one N-amino and two N-amino groups of Lys and stabilized by 6 repeats of Gly-Pro-Hyp. Edman degradation sequence analysis indicated that each of the 10 crude THPs contained at least 50% of the desired product.



The 10 homotrimeric THPs and a generic THP (designated GPP*) containing only eight repeats of Gly-Pro-Hyp were examined for promotion of NHDF adhesion. At a peptide concentration of 0.1 mg/ml, only the THP incorporating alpha1(I)771-786 showed substantial (50%) cell adhesion activity (Fig. 1). None of the other crude THPs showed >10% cell adhesion activity (Fig. 1). The high adhesion of NHDFs to the alpha1(I)772-786 THP was thus examined further.


Figure 1: Promotion of NHDF adhesion by type I collagen, GPP*, or crude THPs incorporating type I collagen sequences. Substrate concentrations were 0.1 mg/ml for peptides and 0.02 mg/ml for type I collagen. Cells were allowed to adhere to peptide- or protein-coated Immulon 1 plates for 30 min at 37 °C. All assays were repeated in triplicate. Conditions are given under ``Experimental Procedures.''



Synthesis and Characterization of alpha1(I)772-786 THP

The alpha1(I)772-786 THP was resynthesized on a larger scale to allow for extensive structural and biological characterization. Several modifications of our previously described procedure (34, 35) were used. The final 6 repeats of Gly-Pro-Hyp, which had previously been coupled manually using Fmoc-Gly-Pro-Hyp(34, 35) , were added stepwise (as Fmoc-Gly, Fmoc-Pro, and Fmoc-Hyp(tBu)) using an automated peptide synthesizer. The THP was purified by a two-step method developed recently(40, 54) . Edman degradation analysis of the purified alpha1(I)772-786 THP gave the sequence (Gly-Pro-Hyp)(6)-Gly-Pro-Gln-Gly-Ile-Ala-Gly-Gln-Arg-Gly-Val-Val-Gly-Leu-Hyp. Laser desorption mass spectrometry analysis gave (M + K) = 9868.7 Da (theoretical (M + K) = 9865 Da). During the purification of alpha1(I)772-786 THP, we isolated a peptide which, by Edman degradation analysis, had the sequence (Gly-Pro-Hyp)(6)-Gly-Pro-Gln-Gly-Ile-Ala-Gly-Gln-Arg-Gly-Val-Val (40) . This peptide was missing the first three amino acids next to the branch (alpha1(I) residues 784-786) and was thus designated alpha1(I)772-783 THP.

The triple-helical conformation of alpha1(I)772-786 THP and alpha1(I)772-783 THP was evaluated by CD spectroscopy. At low temperatures, alpha1(I)772-786 THP exhibited typical features of a collagen-like conformation (Fig. 2), such as a large negative molar ellipticity ([]) at = 200 nm and a positive [] at = 225 nm(55) . As the temperature was increased, [] increased whereas [] decreased (Fig. 2). The negative [] at high temperatures indicates a melted triple-helix. The alpha1(I)772-783 THP had similar CD spectral characteristics (data not shown). The thermal stabilities of alpha1(I)772-786 THP and alpha1(I)772-783 THP were studied by measuring [] as a function of temperature. When the temperature was increased from 10 °C to 80 °C, alpha1(I)772-786 THP showed a structural transition (triple-helix ⇔ coil) with a midpoint (T(m)) of 43 °C (Fig. 3). The alpha1(I)772-783 THP also showed a transition over this temperature range, with T(m) = 36 °C (Fig. 3). Both THPs had sufficiently stable triple-helical structures to allow for cellular assaying.


Figure 2: CD spectra of purified alpha1(I)772-786 THP in acetic acid/water (1:99) at 10 °C and 80 °C. Spectra were recorded at alpha1(I)772-786 THP = 0.13 mM.




Figure 3: Thermal transition curves for purified alpha1(I)772-786 THP (solid line) and alpha1(I)772-783 THP (dashed line) in acetic acid/water (1:99) at alpha1(I)772-786 THP = 0.13 mM and alpha1(I)772-783 THP = 0.11 mM. Molar ellipticities ([]) were recorded at = 225 nm while the temperature was increased from 10 °C to 80 °C.



Adhesion of Normal Human Dermal Fibroblasts to alpha1(I)772-786 THP and Analogs

Biological studies proceeded with the following peptides: alpha1(I)772-786 THP, alpha1(I)772-783 THP, alpha1(I)772-786 SSP, and GPP* (see Fig. 4for structures). Cellular recognition of the alpha1(I)772-786 sequence was studied initially by comparing NHDF adhesion to the crude and purified alpha1(I)772-786 THP over a concentration range of 0.2-10 µM (Fig. 5). Both the crude and purified alpha1(I)772-786 THP showed concentration-dependent promotion of NHDF adhesion. At a peptide concentration of 2 µM, the crude THP promoted cell adhesion to a level of 26% while the purified THP promoted cell adhesion to a level of 52% (Fig. 5). Purification of the alpha1(I)772-786 THP thus enhanced the promotion of NHDF adhesion. Interestingly, the purified peptide containing the carboxyl-terminal deletion of 3 amino acids (alpha1(I)772-783 THP) had low levels (<10%) of adhesion-promoting activity over the concentration range of 0.2-10 µM (Fig. 5).


Figure 4: Structures of alpha1(I)772-786 THP, alpha1(I)772-783 THP, alpha1(I)772-786 SSP, and GPP*. The THP is composed of a carboxyl-terminal branch generated from 2 Lys residues, one alpha1(I)772-786 sequence per chain and six Gly-Pro-Hyp repeats per chain. GPP* is composed of the carboxyl-terminal branch and eight Gly-Pro-Hyp repeats per chain.




Figure 5: Promotion of NHDF adhesion by crude alpha1(I)772-786 THP (closed circles), purified alpha1(I)772-786 THP (closed squares), and purified alpha1(I)772-783 THP (closed triangles). Cells were allowed to adhere to peptide-coated Immulon 1 plates for 30 min at 37 °C. All assays were repeated in at least triplicate. Conditions are given under ``Experimental Procedures.''



To study the significance of collagen triple-helical structure on cellular recognition, we compared the NHDF adhesion-promoting ability of the alpha1(I)772-786 THP to the alpha1(I)772-786 SSP (Fig. 6). NHDFs showed a profound preference for binding and adhesion to the THP compared with the SSP. Half-maximal fibroblast cellular adhesion occurred at a THP concentration of 1.6 µM, while less than 10% cell adhesion was seen for the SSP up to a concentration of 10 µM. At a peptide concentration of 100 µM, cell adhesion to the SSP was only 40% of the level promoted by the THP (data not shown). There was no NHDF adhesion to the generic THP containing 8 repeats of Gly-Pro-Hyp (GPP*) (Fig. 6).


Figure 6: Promotion of NHDF adhesion by purified alpha1(I)772-786 THP (closed squares), alpha1(I)772-786 SSP (closed diamonds), and GPP* (closed circles). Cells were allowed to adhere to peptide-coated Immulon 1 plates for 30 min at 37 °C. All assays were repeated in at least triplicate. Conditions are given under ``Experimental Procedures.''



Inhibition of Cell Adhesion to alpha1(I)772-786 THP by Anti-integrin mAbs

The inhibition of NHDF cell adhesion to alpha1(I)772-786 THP was compared for different anti-integrin mAbs (Table 2). Initial experiments compared inhibition of adhesion by normal mouse IgG and the anti-beta(1) and anti-alpha(2) mAbs at varying THP coating concentrations. Inhibition of adhesion was seen for the anti-beta(1) mAb at [THP] = 2.0, 5.1, and 10 µM. The anti-alpha(2) mAb results were somewhat inconclusive. Studies at [THP] = 10 µM suggested that the anti-alpha(1) and anti-alpha(3) may inhibit adhesion to the alpha1(I)772-786 THP and that the anti-alpha(5) integrin subunit mAb was not an inhibitor.



Inhibition of Cell Adhesion to Type I Collagen

To determine the ability of alpha1(I)772-786 SSP and alpha1(I)772-786 THP to inhibit cell adhesion to type I collagen, NHDFs were incubated with increasing peptide concentrations in the range of 0.5-10 µM. Neither the alpha1(I)772-786 SSP nor the alpha1(I)772-786 THP inhibited NHDF adhesion to type I collagen in a concentration-dependent fashion (data not shown). In contrast to the SSP and THP, type I collagen inhibited cell adhesion in a concentration-dependent fashion (data not shown).


DISCUSSION

The dissection of the various biological activities mediated by type I collagen requires an approach by which the influence of triple-helical conformation can be evaluated. More specifically, the mechanisms of collagen catabolism may require two types of cellular recognition sites, those that are dependent upon triple-helical conformation and those that are revealed upon denaturation of the triple-helix. Our initial interest is in identifying sites that are recognized in triple-helical conformation. The alpha(1)beta(1) and alpha(2)beta(1) integrin binding sites are dependent upon triple-helical conformation (56) and contained within alpha1(I)CB3, alpha1(I)CB7, and alpha1(I)CB8 (encompassing residues 124-822 from alpha1(I))(2, 12, 13, 15, 16) . From the 124-822-residue region, we selected sequences that contained ``clusters'' of charged residues. Charged residues are often found in clusters in type I collagen(57) , and cellular activities have been ascribed previously to collagen-derived synthetic peptides that have clustered charged residues(35, 44, 46, 47, 48) . Seven THPs were synthesized based on charge clustering (alpha1(I)256-270, alpha1(I)385-396, alpha1(I)406-417, alpha1(I)415-423, alpha1(I)448-456, alpha1(I)496-507, and alpha1(I)526-537). Three additional THPs were synthesized (alpha1(I)85-96, alpha1(I)433-441, and alpha1(I)772-786) based on previously described or proposed activities(17, 20, 49) .

The 10 THPs were screened for cell adhesion activity without prior purification of the peptides. Edman degradation sequence analysis indicated that each crude THP contained a substantial amount of the desired peptide. Thus, the crude THPs were adequate for screening purposes. Of the 10 THPs, alpha1(I)772-786 THP had the greatest cell adhesion-promoting activity. The other 9 THPs exhibited low levels of activity (<10%), similar to the generic triple-helical peptide GPP*. Although the other THPs may represent active sequences, only the alpha1(I)772-786 THP was pursued in this study.

The large scale synthesis and purification of the alpha1(I)772-786 THP proceeded as described for other THPs(34) , with two important modifications. First, the (Gly-Pro-Hyp)(6) region of the THP was assembled stepwise using individual Fmoc-amino acids, not Fmoc-Gly-Pro-Hyp tripeptide blocks. Stepwise assembly had not been possible previously using Fmoc-Hyp, but was successful with the Fmoc-Hyp(tBu) derivative used here. We believe that tBu side-chain protection of Hyp minimizes interstrand hydrogen bonding. Interstrand hydrogen bonding can be detrimental for efficient peptide assembly (for a recent review, see (58) ). Second, a recently developed two-step RP-HPLC method was used for the purification of alpha1(I)772-786 THP (40) which also allowed for the isolation of the deletion peptide alpha1(I)772-783 THP.

The alpha1(I)772-786 THP was highly active, with half-maximal cell adhesion occurring at a peptide concentration of 1.6 µM. Triple helicity was essential for activity of this sequence, as the non-triple-helical peptide analog (alpha1(I)772-786 SSP) exhibited considerably lower levels (leq40%) of cell adhesion even at peptide concentrations as high as 100 µM. The triple-helical dependence for cell binding to the alpha1(I)772-786 sequence is even more pronounced than for the alpha1(IV)1263-1277 sequence described previously(35) . Within the alpha1(I)772-786 sequence itself, residues 784-786 (Gly-Leu-Hyp) were important for cellular recognition, as the alpha1(I)772-783 THP had greatly reduced cell adhesion activity compared with alpha1(I)772-786 THP.

Adhesion of NHDF to the alpha1(I)772-786 THP is inhibited by an anti-beta(1) integrin subunit mAb. It thus appears that an integrin mediates NHDF binding to alpha1(I)772-786 THP. Our preliminary results were inconclusive, suggesting the alpha(1)beta(1), alpha(2)beta(1), or alpha(3)beta(1) integrin may be involved. It has been shown that fibroblasts use the alpha(2)beta(1) integrin for collagen, but not laminin, binding(59) . Binding of the alpha(2)beta(1) integrin to the alpha1(I)CB7 fragment (residues 552-822) is conformationally dependent(13) , consistent with the conformationally dependent binding of NHDF to alpha1(I)772-786 THP. Alternatively, fibronectin has been proposed as a ``bridge'' for ovarian cell binding to the alpha1(I)757-791 sequence(17) . MMP-1 cleavage of the 775-776 bonds or mutation of alpha1(I) Gln and Ala to Pro dramatically alters fibronectin binding to type I collagen(17, 60) . The alpha(5)beta(1) can mediate chondrosarcoma cell binding to denatured type II collagen via a fibronectin bridge(21) , and thus an integrin may serve a similar function for cell binding via a fibronectin bridge to the alpha1(I)772-786 region of type I collagen. Further investigations are ongoing to definitively determine the integrin(s) utilized for cellular recognition of the alpha1(I)772-786 THP.

One curious result is the ability of the alpha1(I)772-786 THP to promote cell adhesion in a concentration-dependent fashion, but not inhibit cell adhesion to type I collagen. In retrospect, it would have been somewhat surprising if the alpha1(I)772-786 THP did inhibit NHDF binding to type I collagen due to the multiple integrin binding sites within type I collagen. It is also possible that there are interactions between the THP and type I collagen. We have previously demonstrated aggregation of THPs(35) , but have not examined the association of THPs and collagen.

Fibroblast interaction with collagen has tremendous implications for understanding the regulation of collagen metabolism and hence processes such as wound healing. Degradation of collagen may proceed (i) intracellularly following phagocytosis or (ii) extracellularly by MMPs (3, 4, 61) . Fibroblasts both phagocytize type I collagen (3, 4) and produce MMP-1(62) . For fibroblasts, the two mechanisms of collagen catabolism may be inversely correlated(4) . For example, interleukin 1alpha inhibits phagocytosis and enhances pro-MMP-1 release, while transforming growth factor-beta has the opposite effect(4) . There is evidence that suggests that the alpha1(I)772-786 sequence mediates both proposed mechanisms of collagen turnover. We have demonstrated that fibroblasts bind to the triple-helical alpha1(I)772-786 sequence. Internalization of type I collagen by fibroblasts is reduced after collagen is cleaved at the 775-776 bonds(3) . Thus, fibroblast phagocytosis of type I collagen appears to include at least part of the 772-786 region. Several members of the MMP family (MMP-1, MMP-2, and MMP-8) hydrolyze the triple-helical region of type I collagen at position 775 in the collagen chains(27, 63) . Thus, extracellular degradation of type I collagen occurs within the 772-786 region. This region may also regulate MMP production. Prior studies have shown that a SSP incorporating residues alpha1(I)769-783 supports human fibroblast adhesion and induces the production of MMP-1(18, 19, 64) . Although the induction mechanism is unknown, it may be related to alpha(2)beta(1)-mediated binding to type I collagen which results in tyrosine phosphorylation of pp125(65) and induction of MMP-1 mRNA levels(66) . If the alpha(2)beta(1) integrin is indeed the cell surface adhesion molecule that binds alpha1(I)772-786 THP, we would be able to study a discreet cell signaling mechanism that influences collagen metabolism. Also, our alpha1(I)772-786 THP may have even greater activity for promoting cell signaling and MMP production than the alpha1(I)769-783 SSP, as cell adhesion to triple-helical collagen results in considerable up-regulation of protein synthesis compared with denatured collagen(67) .

We view the studies presented here as an encouraging start to understanding the variety of biological activities mediated by type I collagen. As stated by Tuckwell et al.(21) , ``crucially, the demonstration of conformation dependence suggests that linear peptides may be unsuitable (for studying) cell-collagen interactions and implies that more sophisticated methods may be necessary for future studies.'' Our triple-helical peptide approach appears to be a logical one for the identification of conformationally dependent collagen-mediated functions.


FOOTNOTES

*
This work was supported in part by the National Institutes of Health Grants KD 44494, AR 01929, and CA 63671 (to G. B. F.), CA 21463, CA 29995, and EY 09065 (to L. T. F.), and the American Cancer Society. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Present address: Pentapharm Ltd., Dornacherstrasse 112, CH-4147 Aesch, Switzerland.

Allen-Pardee Professor.

**
National Institutes of Health Research Career Development Award. To whom correspondence should be addressed: Dept. of Laboratory Medicine and Pathology, Box 107, 420 Delaware St. S.E., University of Minnesota, Minneapolis, MN 55455. Tel.: 612-626-2446; Fax: 612-625-1121.

(^1)
The abbreviations used are: ECM, extracellular matrix; Ahx, 6-aminohexanoic acid; CB, cyanogen bromide; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; Dde, 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-ethyl; DIEA, N,N-diisopropylethylamine; DIPCDI, N,N`-diisopropylcarbodiimide; DMF, N,N-dimethylformamide; DMPAMP, 4-(2`,4`-dimethoxyphenylaminomethyl)phenoxy; ESMS, electrospray mass spectrometry; FABMS, fast atom bombardment mass spectrometry; Fmoc, N-(9-fluorenyl)methoxycarbonyl; GPP*, N-tris((Gly-Pro-Hyp)(8)-Ahx)-Lys-Lys)-Tyr-Gly; HBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HOBt, 1-hydroxybenzotriazole; mAb, monoclonal antibody; MMP, matrix metalloproteinase; NHDF, normal human dermal fibroblasts; PBS, phosphate-buffered saline solution; RP-HPLC, reversed-phase high performance liquid chromatography; SSP, single-stranded peptide; tBu, tert-butyl; TFA, trifluoroacetic acid; THP, triple-helical peptide.


ACKNOWLEDGEMENTS

We thank Cynthia G. Fields for Edman degradation sequence analyses and RP-HPLC assistance.


REFERENCES

  1. Scharffetter-Kochanek, K., Klein, C. E., Heinen, G., Mauch, C., Schaefer, T., Adelmann-Grill, B. C., Goerz, G., Fusenig, N. E., Krieg, T. M., and Plewig, G. (1992) J. Invest. Dermatol. 98, 3-11 [Abstract]
  2. Perris, R., Syfrig, J., Paulsson, M., and Bronner-Fraser, M. (1993) J. Cell Sci. 106, 1357-1368 [Abstract/Free Full Text]
  3. Knowles, G. C., McKeown, M., Sodek, J., and McCulloch, C. A. G. (1991) J. Cell Sci. 98, 551-558 [Abstract]
  4. van der Zee, E., Everts, V., Hoeben, K., and Beertsen, W. (1995) J. Cell Sci. 108, 3307-3315 [Abstract/Free Full Text]
  5. Baumgartner, H. R. (1977) Thromb. Haemostasis 37, 1-16 [Medline] [Order article via Infotrieve]
  6. Nieuwenhuis, H. K., Akkerman, J. W. N., Wim, P., Houdijk, and Sixma, J. J. (1985) Nature 318, 470-472 [Medline] [Order article via Infotrieve]
  7. Santoro, S. A. (1986) Cell 46, 913-920 [Medline] [Order article via Infotrieve]
  8. Fitzsimmons, C. M., Cawston, T. E., and Barnes, M. J. (1986) Thromb. Haemostasis 56, 95-99 [Medline] [Order article via Infotrieve]
  9. Hawinger, J. (1987) Hum. Pathol. 18, 111-122 [Medline] [Order article via Infotrieve]
  10. Coller, B., Beer, J. H., Scudder, L. E., and Steinberg, M. H. (1989) Blood 74, 182-192 [Abstract]
  11. Zijenah, L. S., and Barnes, M. J. (1990) Thromb. Res. 59, 553-566 [Medline] [Order article via Infotrieve]
  12. Staatz, W. D., Walsh, J. J., Pexton, T., and Santoro, S. A. (1990) J. Biol. Chem. 265, 4778-4781 [Abstract/Free Full Text]
  13. Morton, L. F., Peachey, A. R., Zijenah, L. S., Goodall, A. H., Humphries, M. J., and Barnes, M. J. (1994) Biochem. J. 299, 791-797 [Medline] [Order article via Infotrieve]
  14. Fields, G. B. (1995) Connect. Tissue Res. 31, 235-243
  15. Gullberg, D., Gehlsen, K. R., Turner, D. C., Ahlén, K., Zijenah, L. S., Barnes, M. J., and Rubin K. (1992) EMBO J. 11, 3865-3873 [Abstract]
  16. Saelman, E. U. M., Horton, L. F., Barnes, M. J., Gralnick, H. R., Hese, K. M., Nieuwenhuis, H. K., de Groot, Ph. G., and Sixma, J. J. (1993) Blood 82, 3029-3033 [Abstract]
  17. Kleinman, H. K., McGoodwin, E. B., Martin, G. R., Klebe, R. J., Fietzek, P. P., and Wooley, D. E. (1978) J. Biol. Chem. 253, 5642-5646 [Abstract]
  18. Winkler, J. R., Qian, J. J., and Bhatnagar, R. (1991) J. Cell Biol. 115, 442a
  19. Bhatnagar, R. S., Sorensen, K. R., Scaria, P. V., and Qian, J. J. (1992) FASEB J. 6, A288
  20. Staatz, W. D., Fok, K. F., Zutter, M. M., Adams, S. P., Rodriguez, B. A., and Santoro, S. A. (1991) J. Biol. Chem. 266, 7363-7367 [Abstract/Free Full Text]
  21. Tuckwell, D. S., Ayad, S., Grant, M. E., Takigawa, M., and Humphries, M. J. (1994) J. Cell Sci. 107, 993-1005 [Abstract/Free Full Text]
  22. Rubin, K., Höök, M., Öbrink, B., and Timpl, R. (1981) Cell 24, 463-470 [Medline] [Order article via Infotrieve]
  23. Aumailley, M., and Timpl, R. (1986) J. Cell Biol. 103, 1569-1575 [Abstract]
  24. Vandenberg, P., Kern, A., Ries, A., Luckenbill-Edds, L., Mann, K., and Kühn, K. (1991) J. Cell Biol. 113, 1475-1483 [Abstract]
  25. Kern, A., Eble, J., Golbik, R., and Kühn, K. (1993) Eur. J. Biochem. 215, 151-159 [Abstract]
  26. Norris, W. D., Steele, J. G., Johnson, G., and Underwood, P. A. (1990) J. Cell Sci. 95, 255-262 [Abstract]
  27. Fields, G. B. (1991) J. Theor. Biol. 153, 585-602, and references therein [Medline] [Order article via Infotrieve]
  28. Rao, G. H. R., Fields, C. G., White, J. G., and Fields, G. B. (1994) J. Biol. Chem. 269, 13899-13903 [Abstract/Free Full Text]
  29. Morton, L. F., Hargreaves, P. G., Farndale, R. W., Young, R. D., and Barnes, M. J. (1995) Biochem. J. 306, 337-344 [Medline] [Order article via Infotrieve]
  30. Davis, G. E. (1992) Biochem. Biophys. Res. Commun. 182, 1025-1031 [Medline] [Order article via Infotrieve]
  31. Pfaff, M., Aumailley, M., Specks, U., Knolle, J., Zerwes, H. G., and Timpl, R. (1993) Exp. Cell. Res. 206, 167-176 [CrossRef][Medline] [Order article via Infotrieve]
  32. Berman, A., Morozevich, G., Karmansky, I., Gleiberman, A., and Bychkova, V. (1993) Biochem. Biophys. Res. Commun. 194, 351-357 [CrossRef][Medline] [Order article via Infotrieve]
  33. Ruggiero, F., Champliaud, M.-F., Garrone, R., and Aumailley, M. (1994) Exp. Cell. Res. 206, 167-176 [CrossRef]
  34. Fields, C. G., Lovdahl, C. M., Miles, A. J., Matthias Hagen, V. L., and Fields, G. B. (1993) Biopolymers 33, 1695-1707 [Medline] [Order article via Infotrieve]
  35. Fields, C. G., Mickelson, D. J., Drake, S. L., McCarthy, J. B., and Fields, G. B. (1993) J. Biol. Chem. 268, 14153-14160 [Abstract/Free Full Text]
  36. Wayner, E. A., and Carter, W. G. (1987) J. Cell Biol. 105, 1873-1884 [Abstract]
  37. Fields, G. B., Tian, Z., and Barany, G. (1992) Synthetic Peptides: A User's Guide (Grant, G. A., ed) pp. 77-183, W. H. Freeman & Co., New York
  38. Gausepohl, H., Boulin, C., Kraft, M., and Frank, R. W. (1992) Peptide Res. 5, 315-320
  39. King, D. S., Fields, C. G., and Fields, G. B. (1990) Int. J. Peptide Protein Res. 36, 255-266 [Medline] [Order article via Infotrieve]
  40. Fields, C. G., Grab, B., Lauer, J. L., and Fields, G. B. (1995) Anal. Biochem. 231, 57-64 [CrossRef][Medline] [Order article via Infotrieve]
  41. Fields, C. G., Lloyd, D. H., Macdonald, R. L., Otteson, K. M., and Noble, R. L. (1991) Peptide Res. 4, 95-101
  42. Fields, C. G., VanDrisse, V. L., and Fields, G. B. (1993) Peptide Res. 6, 39-47
  43. Fields, C. G., Loffet, A., Kates, S. A., and Fields, G. B. (1992) Anal. Biochem. 203, 245-251 [Medline] [Order article via Infotrieve]
  44. Miles, A. J., Skubitz, A. P. N., Furcht, L. T., and Fields, G. B. (1994) J. Biol. Chem. 269, 30939-30945 [Abstract/Free Full Text]
  45. Miles, A. J., Knutson, J. R., Skubitz, A. P. N., Furcht, L. T., McCarthy, J. B., and Fields, G. B. (1995) J. Biol. Chem. 270, 29047-29050 [Abstract/Free Full Text]
  46. Chelberg, M. K., McCarthy, J. B., Skubitz, A. P. N., Furcht, L. T., and Tsilibary, E. C. (1990) J. Cell Biol. 111, 261-270 [Abstract]
  47. Wilke, M. S., and Furcht, L. T. (1990) J. Invest. Dermatol. 95, 264-270 [Abstract]
  48. Cameron, J. D., Skubitz, A. P. N., and Furcht, L. T. (1991) Invest. Ophthalmol. Vis. Sci. 32, 2766-2773 [Abstract]
  49. San Antonio, J. D., Lander, A. D., Karnovsky, M. J., and Slayter, H. S. (1994) J. Cell Biol. 125, 1179-1188 [Abstract]
  50. Bornstein, P., and Traub, W. (1979) The Proteins (Neurath, H., and Hill, R. L., eds) 3rd Ed., Vol. IV, pp. 411-632, Academic Press, New York
  51. Tromp, G., Kuivaniemi, H., Stacey, A., Shikata, H., Baldwin, C. T., Jaenisch, R., and Prockop, D. J. (1988) Biochem. J. 253, 919-922 [Medline] [Order article via Infotrieve]
  52. Labhard, M. E., and Hollister, D. W. (1990) Matrix 10, 124-130 [Medline] [Order article via Infotrieve]
  53. Li, S.-W., Khillan, J., and Prockop, D. J. (1995) Matrix Biol. 14, 593-595 [Medline] [Order article via Infotrieve]
  54. Grab, B., Furcht, L. T., and Fields, G. B. (1996) Peptides: Chemistry, Structure and Biology (Kaumaya, P. T. P., and Hodges, R. S., eds.) pp. 603-604, Mayflower Scientific, West Midlands, UK
  55. Heidemann, E., and Roth, W. (1982) Adv. Polym. Sci. 43, 143-203
  56. Kühn, K., and Eble, J. (1994) Trends Cell Biol. 4, 256-261 [CrossRef]
  57. Dölz, R., and Heidemann, E. (1986) Biopolymers 25, 1069-1080 [Medline] [Order article via Infotrieve]
  58. Fields, C. G., and Fields, G. B. (1994) Methods in Molecular Biology (Pennington, M. W., and Dunn, B. M., eds) Vol. 35, pp. 29-40, Humana Press, Totowa, NJ
  59. Elices, M. J., and Hemler, M. E. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 9906-9910 [Abstract]
  60. Dzamba, B. J., Wu, H., Jaenisch, R., and Peters, D. P. (1993) J. Cell Biol. 121, 1165-1172 [Abstract]
  61. Sodek, J., and Overall, C. M. (1988) The Biological Mechanisms of Tooth Eruption and Root Resorption (Davidovitch, D., ed) Vol. 2, pp. 303-312, EBSCO, Birmingham, AL
  62. Werb, Z., and Reynolds, J. J. (1974) J. Exp. Med. 140, 1482-1497 [Medline] [Order article via Infotrieve]
  63. Aimes, R. T., and Quigley, J. P. (1995) J. Biol. Chem. 270, 5872-5876 [Abstract/Free Full Text]
  64. Qian, J. J., Rosen, M. A., and Bhatnagar, R. (1992) FASEB J. 7, A1306
  65. Polanowska-Grabowska, R., Geanacopoulos, M., and Gear, A. R. L. (1993) Biochem. J. 296, 543-547 [Medline] [Order article via Infotrieve]
  66. Riikonen, T., Westermarck, J., Koivisto, L., Broberg, A., Kähäri, V.-M., and Heino, J. (1995) J. Biol. Chem. 270, 13548-13552 [Abstract/Free Full Text]
  67. Koseki, N., and Yoshizato, K. (1994) Cell Adhesion Commun. 1, 355-366 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.